Full-Time

Senior DevSecOps Engineer

Deadline 8/31/26
Haleon

Haleon

10,001+ employees

Global consumer health care products company

No salary listed

Bengaluru, Karnataka, India

In Person

Category
DevOps & Infrastructure (1)
Required Skills
PowerShell
Datadog
Bash
Microsoft Azure
Agile
Python
JavaScript
GitHub Actions
Data Visualization
SonarQube
Infrastructure as Code (IaC)
Docker
Terraform
Observability
MongoDB
DevOps

Get referred to Haleon

See people who can refer or advise you

Requirements
  • Strong hands-on experience administering GitHub Enterprise, GitHub Advanced Security, Azure DevOps, and enterprise continuous integration and continuous delivery pipelines.
  • Solid understanding of Azure cloud services, Entra ID identity and access management, network security, least-privilege principles, and secure workload design.
  • Proven expertise in static application security testing, software composition analysis, secret scanning, vulnerability triage, and governance workflows.
  • Experience securing and operating Azure Kubernetes Service, Azure Container Registry, and containerized applications.
  • Proficiency in Terraform, Terraform Cloud, module development, policy enforcement, and remote backends.
  • Strong scripting skills in YAML, Bash, and PowerShell, with expected proficiency in Python and JavaScript.
  • Proficiency in Python and JavaScript coding to support automation, security-tool integration, and developer workflows.
  • Strong understanding of coding standards aligned with software development lifecycle best practices, software compliance, and secure coding standards.
  • Experience working with software-as-a-service platforms and strong understanding of platform security and integration patterns.
  • Ability to troubleshoot complex continuous integration and continuous delivery, pipeline, GitHub, Azure DevOps, or container-security issues end to end.
  • Experience working in global, multi-region, regulated environments.
Responsibilities
  • Administer and optimize GitHub Enterprise Cloud, GitHub Enterprise Server, Azure DevOps, SonarQube, Datadog SAST, and Docker Desktop at enterprise scale.
  • Define and enforce organization-wide governance for branch protection, repository standards, permissions, audit logging, SSO/SCIM, and GitHub Actions/Azure DevOps runner governance.
  • Implement and manage GitHub Advanced Security features, including CodeQL, Dependabot, secret scanning with push protection, and SAST, SCA, DAST, infrastructure-as-code scanning, and artifact-signing integrations in pipelines.
  • Support evaluation, onboarding, and migration of next-generation security tools, including Datadog Code Security and SonarQube-to-Datadog proofs of concept.
  • Govern security across GitHub Actions and Azure DevOps continuous integration and continuous delivery pipelines, including secure release workflows, multistage approvals, environment protections, and quality gates.
  • Support teams in designing and deploying secure applications on Azure in alignment with cloud-security best practices.
  • Implement infrastructure-as-code best practices using Terraform Cloud and native Terraform, including policy checks, workspace governance, remote backends, and drift detection.
  • Maintain hardened Docker base images, enforce secure container usage, and ensure compliance across Azure Kubernetes Service and Azure Container Registry environments.
  • Build actionable dashboards, alerts, and audit-ready evidence pipelines for observability and compliance.
  • Provide Level 3 operational support for DevSecOps platforms, handle escalations, and resolve complex incidents.
  • Track and publish DevSecOps adoption, security-posture metrics, and platform-coverage insights.
  • Lead remediation sprints, proofs of concept, platform upgrades, migrations, maintenance activities, and broader architectural improvements.
  • Collaborate with Cloud, Security, Platform Engineering, and Product teams to address cross-functional engineering challenges.
  • Drive improvements in developer productivity and experience through self-service infrastructure provisioning, developer portals, and Internal Developer Platform capabilities.
  • Enable and support standardized development workflows to improve onboarding, consistency, and delivery efficiency across teams.
  • Participate in Agile delivery activities, including sprint planning, backlog refinement, daily stand-ups, sprint reviews, and retrospectives.
  • Support and leverage Azure-native engineering capabilities, including Azure Kubernetes Service, Azure Functions, Azure DevOps, GitHub Actions, Azure Developer CLI, and Terraform with AzureRM.
Desired Qualifications
  • Exposure to DaaS platforms, particularly MongoDB Atlas.
  • Microsoft Certified: Azure DevOps Expert, Certified Kubernetes Application Developer, or equivalent certifications.

Haleon is a global consumer health company that develops and sells everyday health products under brands such as Sensodyne, Advil, and Centrum. Its products address oral care, pain relief, immunity, and general well-being, working through science-backed formulations people use daily. Haleon differentiates itself by being a focused, standalone consumer health business formed from GSK’s spin-off and built from leading brands through major acquisitions, operating at scale with a portfolio of category leaders and competing with peers like Kenvue and Procter & Gamble. Its goal is to help people take control of their daily health with trusted products, while expanding its global reach and investing in manufacturing capacity and brand development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Weybridge, United Kingdom

Founded

2022

Get referred to Haleon

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • H1 2026 organic growth reached 2.6%; Q2 improved to 3.1% with North America rebound.
  • Emerging markets grew 6.3% in Q2 2026, led by China, India, and Latin America.
  • Haleon priced a $2 billion bond on August 13, 2026, refinancing March 2027 notes.

What critics are saying

  • Haleon terminated Eroxon U.S. rights on June 29, 2026 after slower-than-expected sales.
  • July 30, 2026 litigation revived claims over Advil Sinus maximum-strength labeling.
  • June 4, 2026 Gas-X recall and sub-4% growth against a 4%-6% target threaten valuation.

What makes Haleon unique

  • Haleon owns category-leading brands like Sensodyne, Advil, Panadol, and Centrum across 170 markets.
  • Its June 29, 2026 Microsoft partnership embeds AI across operations, data, and productivity.
  • Oral health innovation keeps driving share gains; H1 2026 oral health grew 7.3%.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Paid Parental Leave

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Investegate
Aug 13th, 2026
Haleon prices $2B bond offering to repurchase 2027 notes

Haleon's US subsidiary, Haleon US Capital LLC, has launched and priced a $2 billion fixed-rate bond offering. The offering comprises three tranches: $600 million in notes maturing in 2029 with a 4.625% coupon, $600 million in notes maturing in 2031 with a 4.875% coupon, and $800 million in notes maturing in 2036 with a 5.375% coupon. The offering is scheduled to settle on 21 August 2026. Payment of principal and interest is fully guaranteed by Haleon plc. The company plans to use the net proceeds, together with cash on hand if necessary, to repurchase its outstanding $1,999,350,000 3.375% fixed rate senior notes due March 2027 and for general corporate purposes. Barclays Capital, BofA Securities, Deutsche Bank Securities, Goldman Sachs and Mizuho Securities acted as joint book-running managers.

CCentral
Aug 4th, 2026
Daniela Cavinatto appointed general manager of Canada division for Haleon Canada.

Daniela Cavinatto appointed general manager of Canada division for Haleon Canada. Daniela Cavinatto joins the consumer health company with more than 25 years of international leadership experience. Haleon Canada has appointed Daniela Cavinatto as its new general manager of the Canada division. Cavinatto joins the consumer health company with more than 25 years of international leadership experience. In her new position, she will lead Haleon's Canadian operations as the company works to strengthen its market leadership and expand its portfolio of consumer health brands, including Advil, Sensodyne, and Centrum. Industry experience across global markets. Prior to joining Haleon, Cavinatto served as general manager, Canada for The LEGO Group. During her time there, she led business growth by redefining market strategy, strengthening customer partnerships, and optimizing commercial investments. Throughout her career, Cavinatto has held senior executive roles across North America, Latin America, and Europe. Her background spans general management, sales, marketing, customer development, eCommerce, retail operations, and supply chain. "Daniela is an accomplished business leader with a proven ability to unlock growth, navigate complexity and deliver results in dynamic markets," said Nathalie Gerschtein, the Haleon North America president. "Canada is an important growth market for Haleon, and Daniela brings the commercial acumen, global perspective and leadership experience needed to help us build on our momentum. I am delighted to welcome Daniela to our North American leadership team and look forward to working with her as we strengthen our trusted brand portfolio and advance our leadership in consumer health." Portfolio reach and growth strategy. Haleon's Canadian product lineup holds a strong presence across retail channels. According to the company, six in 10 Canadian households rely on at least one Haleon brand. As of last year, the 2025 Product of The Year lineup included Tums Chewy Bites with Gas Relief. Cavinatto noted that the reach of the company's product line made the role an exciting opportunity. "Throughout my career, I've been inspired by opportunities to transform businesses, accelerate growth and help teams achieve ambitious goals," Cavinatto said. "That's what makes this opportunity so compelling. Haleon's portfolio of brands is rooted in science and consumer understanding with six in 10 Canadian households relying on at least one of our iconic brands. To lead a business with this kind of reach and impact is a true privilege and an opportunity that deeply inspires me." She added that she looks forward to working with internal teams, retail customers, and commercial partners to support the company's continued growth and innovation across Canada.

Yahoo Finance
Aug 1st, 2026
Haleon H1 2026: Organic growth hits 3.1%, margins up 120bp as North America rebounds

Haleon reported H1 2026 results ending 30 July, showing improved organic sales growth of 3.1% in Q2, with volume and mix up 1.4%. North America delivered strong progress at 3.1% growth, driven by shelf resets, innovation, and e-commerce momentum. Operating margin improved 120 basis points at constant currency, supported by supply chain efficiency and gross margin expansion of 140 basis points. Emerging markets achieved 6.3% growth in Q2, with India and Latin America leading performance. EPS grew 12% in H1. However, respiratory health remained weak, reducing organic growth by 150 basis points. Europe proved challenging with only 0.4% growth, whilst Middle East markets including Dubai and Pakistan experienced significant declines. The company acknowledged performing below its 4–6% medium-term growth target, with particular gaps in Europe and the Middle East.

Sharecast
Jul 30th, 2026
Oral health drives first-half growth at Haleon.

Oral health drives first-half growth at Haleon. 368.40p. 11:52 30/07/26. Haleon reported first-half revenue of £5.60bn on Thursday, up 2.2% on a reported basis and 2.6% organically, with second-quarter organic growth improving to 3.1% as North America strengthened. 10,913.70. 5,926.86. 5,860.81. 24,761.16. 11:51 30/07/26. Adjusted operating profit rose 8.2% at constant currencies to £1.36bn and the adjusted operating margin increased to 24.3%, while adjusted diluted earnings per share rose 12% to 10.3p. Oral Health was the strongest category, with second-quarter growth of 6.2%, while emerging markets grew 6.3%. The consumer healthcare group reiterated its full-year guidance for organic revenue growth of 3% to 5% and high-single-digit adjusted operating profit growth at constant currencies. "We delivered a good first half performance in what remains a challenging consumer environment, with sequential improvement in Q2 and a more balanced price and volume/mix," said chief executive Brian McNamara. Haleon also raised its interim dividend 9% to 2.4p and said it had completed £457m of its planned £500m share buyback for 2026. At 0947 BST, shares in Haleon were down 2.03% at 372p. Reporting by Josh White for Sharecast.com.

KamCity
Jul 29th, 2026
Maker of Panadol launches new dual-action Pain Relief Tablets.

Maker of Panadol launches new dual-action Pain Relief Tablets. 29th July 2026 Haleon, the maker of Panadol, is expanding into the dual-action pain relief market with the launch of Panacombo Dual Action Pain Relief 200mg/500mg Film-coated Tablets (ibuprofen & paracetamol). The formulation of two pain-relieving ingredients is designed to be stronger and faster than ibuprofen alone, delivering effective pain relief from multiple pain types, including migraine, headache, backache, dental pain, period pain, joint or muscular pain, and aches linked with cold and flu. Haleon noted that Ibuprofen acid alone only provides effective pain relief in 37-45% of cases, while combining ibuprofen with paracetamol increases effectiveness to 67-70%, highlighting the enhanced pain relief achievable through a combined approach. Expanding the trusted Panadol range, Panacombo Dual Action Tablets are formulated to give your shoppers dual relief in one tablet. Paracetamol helps to block pain signals, and ibuprofen helps stop pain at the source. Monica Michalopoulou, Marketing Director at Haleon, said: "For 70 years, Panadol have been experts in pain relief, trusted to assist consumers with pain when needed. The launch of Panacombo, our dual-action pain-relief solution, expands our range of trusted products, and will offer retailers a strong proposition to help boost sales, encouraging shoppers to trade up and benefit from our trusted brand credentials." Panacombo Dual Action Tablets are rolling out in grocery stores at an RRP of £3.50. The launch will be supported by a wide-reaching consumer media activation and campaign later in the year.